The periodic monitoring of serum markers (like chromogranin A, neuron-specific enolase), circulating tumor cells, and circulating tumor DNA/RNA could aid in detecting the development of transdifferentiation or treatment resistance. The gene discussed is CHGA; the disease is neoplasm.